Dr. Arnold Glazier graduated from Roxbury Latin High School and Boston University Six-Year Medical School Program. He trained in Pediatrics at Johns Hopkins Hospital and Tufts New England Medical Center and was then a Research Fellow in Oncology at Johns Hopkins Oncology Center. He spent several years gaining practical experience in medicinal chemistry in the Laboratory of Professor George Wright, Ph.D. Dept. of Pharmacology, University of Massachusetts Medical School. For six years, he was a visiting Research Associate in the Department of Biochemistry, Brandeis University. Dr. Glazier, practiced pediatrics part-time for 13 years. For the last ten years, he has devoted full-time to cancer research and drug design.
In 1991, Dr. Glazier founded Drug Innovation and Design, Inc. (DIAD) He was responsible for the design and development of an anti-viral drug that successfully completed Phase I clinical trials. In 1998, Dr. Glazier began an intensive project to totally re-think the problem of cancer. This work led to an understanding of the logical implications of tumor cell evolution, the discovery of the theoretical requirements for the specific cure of cancer and the invention of Pattern Recognition Tumor Targeting. Dr. Glazier's book: Cure: Scientific, Social, and Organizational Requirements for the Specific Cure of Cancer was the catalyst that led to the formation of the Cure Cancer Project.